Insider Purchases: Inside the Buy
Tag: MedTech
👁️ CooperCompanies (COO): Insiders Buy $1.33M at $53–$54 as the Stock Crashes
Three CooperCompanies directors just put $1.33 million of their own money into COO near $53–$54. Add record $273M free cash flow, an expanded $3B buyback authorization and an 11.1× forward P/E—and this beaten-down medtech stock deserves a much closer look. 👁️
🩺 Alphatec (ATEC): CEO’s $1M Buy, Positive Free Cash Flow & an 11% Short-Squeeze Fuse 🦾🦴
Alphatec CEO Pat Miles just put $1.01 million of his own money into ATEC at $8.81. With positive free cash flow, improving EBITDA, Valence robotics and 11% short interest, is this battered spine-medtech stock finally reaching its turnaround moment?
🦴 Enovis (ENOV): CEO Buys the $19 Crash—Is This Falling Knife Finally a Buy? 🤖
Enovis CEO Damien McDonald bought ENOV again after shares collapsed toward $19. Insiders are accumulating, institutions remain heavily invested, analysts see substantial upside and adjusted valuation has fallen below 5x forward earnings. But short interest is high, leverage and integration risks remain—and momentum is dreadful. ENOV may be the ultimate FunStock signal collision.
🫀 Boston Scientific (BSX): The CEO Just Bought $9 Million. Is Wall Street Missing Something?
Boston Scientific's stock has been cut nearly in half from its peak, yet the business remains fundamentally strong. With CEO Mike Mahoney buying $9 million worth of shares, a remarkably low 0.71 PEG ratio, billions in annual free cash flow, and overwhelming institutional ownership, is Wall Street overlooking one of healthcare's most attractive GARP opportunities?
🫀 Boston Scientific (BSX): A GARP Reset on a Medical Device Powerhouse
Boston Scientific stock has fallen nearly 48% from its highs, but the business engine remains strong. With double-digit revenue growth, major cardiovascular catalysts, director insider buying, low short interest, and a $2B buyback, BSX may be one of the cleaner large-cap healthcare GARP setups on the market.
🩺 GE HealthCare (GEHC): Insider Buying, AI Growth & a $21B Backlog Opportunity
GE HealthCare (GEHC) is quietly shaping up as a high-visibility MedTech play, combining insider buying, a $21.8B backlog, and AI-driven diagnostics. With valuation still reasonable and institutional ownership near record levels, this could be a compelling long-term compounder—if you’re patient on entry.
PODD Stock Analysis 2026: Is Insulet the Ultimate Growth Play or a Valuation Trap?
Insulet (PODD) just delivered 31% revenue growth and insiders are buying — yet the stock trades at 70x earnings. Is this premium medtech compounder a long-term winner or priced for perfection? Here’s the FUNanc1al breakdown.
Director Purchases Shares of Johnson & Johnson
A director just slapped fresh cash on Johnson & Johnson stock. With a AAA credit rating, a 100+ year history, blockbuster drugs, cutting-edge MedTech, and a valuation that’s more “fair” than “fire sale,” should retail investors follow—or wait for a better entry point?
AngioDynamics (ANGO)’s CEO Bought Shares a Year Ago and Stock Doubled Since: Will They Keep Going Higher?
AngioDynamics insiders bought low and doubled up, while Wall Street funds practically own the company. With MedTech sales surging and earnings around the corner, can $ANGO climb higher — or will tariffs and volatility zap the gains?
This Wound Care Stock Doesn't Have to Hurt! 🩸🩼
CEO Joseph Capper is buying big. The company’s 9% full-year sales growth and 20%+ EBITDA margins suggest something’s brewing at this placental powerhouse. From PURION™ to profitability—this is wound care with a serious upside.